Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 11, 2008. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a regulatory disclosure of share ownership changes and does not contain financial performance data.
Material Changes
The material change reported is the acquisition of Ordinary shares by nine individuals through the Company's ShareReward Plan on July 10, 2008. The shares were purchased at a price of £12.41 per Ordinary share under the Dividend Reinvestment element of the Plan.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of specific share transactions in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: July 10, 2008.
- Share Price: £12.41 per Ordinary share.
- Participants: Mr A P Witty, Mr C Viehbacher, Mr J S Heslop, Mr S M Bicknell, Mr E J Gray, Mr D Learmouth, Dr D Pulman, Mr D S Redfern, and Ms C Thomas.
- Acquisition Volume: Most participants acquired 17 shares; Mr C Viehbacher acquired 3 shares; Dr D Pulman acquired 8 shares.
- Mechanism: Dividend Reinvestment element of the ShareReward Plan (entered October 5, 2001).